Clinical trials: Post-ERCP Acute Pancreatitis
Post-ERCP Acute Pancreatitis
Rectal Indomethacin to Prevent Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis
The purpose of this study is to assess whether peri-procedural administration of rectal indomethacin, compared to placebo, can reduce the incidence of post-ERCP pancreatitis.
- Trial name
- NCT01774604
- Testing
- Indomethacin
- Where
- United States
- Volunteers
- 449 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Post-ERCP Acute Pancreatitis, Cholangitis
ERCP in Super-aged Patients Considering Difficult Cannulation: Challenges and Adverse Events
Today 11 percent of China's population is over the age of 65, and according to United Nations, it will take China just 20 years for the proportion of the elderly population to double to 25%.
- Trial name
- NCT03771547
- Testing
- ERCP
- Where
- China
- Volunteers
- 614 people
- Sponsor
- The Second Hospital of Nanjing Medical University
Post-ERCP Acute Pancreatitis
7 cm vs. 5 cm Pancreatic Stents for the Prevention of Post-ERCP Pancreatitis in High-risk Patients
Acute pancreatitis is the most common complication of endoscopic retrograde cholangiopancreatography (ERCP). The incidence of post-ERCP pancreatitis (PEP) is estimated to be 10% to 15% in high-risk patients.
- Trial name
- NCT04145336
- Testing
- 5cm 5-Fr PDS, 7cm 5-Fr PDS, Indomethacin
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Air Force Military Medical University, China
Pancreatitis, Acute
Cold and NSAID Trial for Prevention of Post-ERCP Pancreatitis
The standard prophylaxis for post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) is performed with rectal non-steroidal anti-inflammatory drugs (NSAIDs).
- Trial name
- NCT07738094
- Testing
- NSAID alone, Cryoprevention associated with NSAID
- Where
- Brazil
- Volunteers
- 583 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Post-ERCP Acute Pancreatitis, NSAIDs
Prevention of Post-ERCP Pancreatitis by Indomethacin vs Diclofenac
Post-ERCP pancreatitis (PEP) is the most common complication after ERCP, which was associated with occasional mortality, prolonged hospital days and increased health costs.
- Conditions
- Post-ERCP Acute Pancreatitis, NSAIDs, Indomethacin, Diclofenac
- Trial name
- NCT05947461
- Testing
- 100mg diclofenac, 100mg indomethacin
- Where
- 11 sites in China
- Volunteers
- 1,204 people
- Sponsor
- Air Force Military Medical University, China
Post-ERCP Acute Pancreatitis, Pancreatic Stent
Establishing a Sonographic Based Algorithm to Verify Pancreatic Stent Position Placed to Prevent Post-ERCP Pancreatitis Before Endoscopic Removal
The present study is a prospective, single-center study. A total of 88 patients, who had placed a pancreatic stent for preventing post-ERCP pancreatitis, will be included in the study.
- Conditions
- Post-ERCP Acute Pancreatitis, Pancreatic Stent, Ultrasound, X-rays
- Trial name
- NCT04546867
- Testing
- Sonographic based visualization of a pancreatic stent
- Where
- Germany
- Volunteers
- 88 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Post-ERCP Acute Pancreatitis
Somatostatin, Octreotide, Pentoxyfilline in the Prevention of Post-ERCP Pancreatitis and Molecular Markers
Octreotide, somatostatin and pentoxyfilline commercially available drugs that are used in various clinical situations. They are safe and known for years.
- Trial name
- NCT00222092
- Where
- Greece
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Ioannina
Post-ERCP Acute Pancreatitis
ERCP-induced and Non-ERCP Induced Acute Pancreatitis: Two Distinct Clinical and Immunological Entities?
Post endoscopic pancreatitis (PEP) has different initial immunologic response to primary injury compared to acute pancreatitis of other etiology (non-PEP AP).
- Trial name
- NCT02602574
- Testing
- heparinized peripheral venous blood and urine sample.
- Where
- Croatia
- Volunteers
- 66 people
- Sponsor
- University Hospital Rijeka
Post-ERCP Acute Pancreatitis
An European Multi-centre Cohort Study for Unravelling Pharmacokinetic and Genetic Factors Underlying Post-ERCP Pancreatitis
Endoscopic retrograde cholangiopancreatography (ERCP) comes with a risk for post-ERCP pancreatitis (PEP), which accounts for considerable morbidity, high healthcare expenditure, and death.
- Trial name
- G-PEP (NCT05267379)
- Testing
- Take blood samples
- Where
- Netherlands
- Volunteers
- 700 people
- Sponsor
- Radboud University Medical Center
Post-ERCP Acute Pancreatitis
A Prospective Trial of Aggressive Hydration Strategy to Reduce Post-ERCP Pancreatitis
Postendoscopic retrograde cholangiopancreatography pancreatitis is the most frequent and serious complication of ERCP procedures, occurring in approximately 5-15% of unselected patients.
- Trial name
- NCT02308891
- Testing
- lactated Ringer's solution (vigorous hydration arm), lactated Ringer's solution (standard hydration arm), endoscopic retrograde cholangiopancreatography (ERCP)
- Where
- 3 sites in South Korea
- Volunteers
- 510 people, healthy volunteers welcome
- Sponsor
- Dankook University
Post-ERCP Acute Pancreatitis
Rectal Indomethacin and Oral Tacrolimus Versus Combination to Prevent Post-ERCP Pancreatitis
This research is being done to see if using oral tacrolimus before endoscopy, can prevent pancreatitis that may occur after ERCP (a type of gastrointestinal endoscopy).
- Trial name
- INTRO (NCT05252754)
- Testing
- Tacrolimus capsule, Rectal Indomethacin
- Where
- 5 sites in United States, India and 1 more
- Volunteers
- 4,874 people
- Sponsor
- Johns Hopkins University
Post-ERCP Acute Pancreatitis.
Diclofenac vs. Placebo in a Randomized Double Blind Controlled Trial in Post ERCP Pancreatitis
1. The most common complication of endoscopic retrograde cholangio-pancreaticography (ERCP) is pancreatitis. 2. Several studies showed that non-steroidal anti-inflammatory drugs (NSAIDs) can prevent the post ERCP pancreatitis…
- Trial name
- NCT01946984
- Testing
- ERCP, Diclofenac hydroxyethylpyrrolidine, Normal Saline
- Where
- Palestinian Territories
- Volunteers
- 182 people
- Sponsor
- Specialized Arab Hospital
Post-ERCP Acute Pancreatitis
PAN-PROMISE to Detect Post-ERCP Pancreatitis Symptoms
The aim of this study is to use a validated patient-reported outcome measure to evaluate how many patients have symptoms of pancreatitis after ERCP and how it correlates with their quality of life and productivity.
- Trial name
- PAN-PROMISE (NCT05310409)
- Where
- 2 sites in United States
- Volunteers
- 700 people
- Sponsor
- University of Pennsylvania
Post-ERCP Acute Pancreatitis
Urine Trypsinogen 2 Dipstick for the Early Detection of Post-ERCP Pancreatitis
Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is the most common, serious complication of ERCP. More than 500,000 ERCP procedures are performed from which 25,000 cases of PEP occur in the U.S.A.
- Trial name
- NCT03098082
- Testing
- Actim Pancreatitis
- Where
- United States
- Volunteers
- 394 people
- Sponsor
- Indiana University
Acute Biliary Pancreatitis
Prophylactic Sphincterotomy in Acute Biliary Pancreatitis Patients Unfit for Surgery
This is a prospective, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of prophylactic endoscopic sphincterotomy (ES) in frail patients unfit for cholecystectomy following an…
- Trial name
- PROSECCO (NCT07238296)
- Testing
- Prophylactic endoscopic sphincterotomy
- Volunteers
- 92 people
- Sponsor
- Semmelweis University
Bile Duct Diseases, Biliary Tract Diseases
Safety and Efficacy Study of IL-10 (Tenovil TM) in the Prevention of Post-ERCP Acute Pancreatitis (Study P02580)(TERMINATED)
The purpose of this study is to determine if a single dose of IL-10 compared to placebo is safe and effective in reducing the incidence of post-ERCP acute pancreatitis for subjects with increased risk.
- Conditions
- Bile Duct Diseases, Biliary Tract Diseases, Gallbladder Diseases, Pancreatitis
- Trial name
- NCT00040131
- Testing
- IL-10
- Volunteers
- 316 people
- Sponsor
- Merck Sharp & Dohme LLC
Post-ERCP Acute Pancreatitis
Statins and Post-ERCP Acute Pancreatitis (Stark Project)
Post-endoscopic retrograde cholangiopancrepatography (ERCP) acute pancreatitis (PEAP) is a frequent complication of this endoscopic procedure.
- Trial name
- Stark (NCT06367322)
- Testing
- Statin
- Where
- 2 sites in Spain
- Volunteers
- 1,016 people
- Sponsor
- Hospital General Universitario de Alicante
Post-ERCP Acute Pancreatitis
Randomized Controlled Trial of Rectal Indomethacin Versus Combined Pancreatic Stent Placement and Rectal Indomethacin for Preventing Post-ERCP Pancreatitis
The goal of this clinical trial is to compare rectal indomethacin alone versus combined pancreatic duct stenting and rectal indomethacin in prevention of post ERCP pancreatitis.
- Trial name
- NCT05857514
- Testing
- Rectal Indomethacin, Prophylactic Pancreatic duct stenting
- Where
- 2 sites in India
- Volunteers
- 384 people
- Sponsor
- Moti Lal Nehru Medical College
Pancreatitis, Acute
Epinephrine Sprayed on the Papilla Versus Sterile Water Sprayed on the Papilla for Preventing Pancreatitis After Endoscopic Retrograde Cholangiopancreatography
This multicentre randomised controlled trial included patients aged >18 years with an indication for ERCP and naive major papilla.
- Trial name
- NCT02959112
- Testing
- Epinephrine, Sterile water, Indomethacin Rectal Suppository
- Where
- Mexico
- Volunteers
- 548 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Post-ERCP Acute Pancreatitis
Incidence and Risk Factor of Post-ERCP Pancreatitis in Chronic Pancreatitis
The purpose of this study is to compare the incidence of post-ERCP pancreatitis (PEP) in chronic pancreatitis (CP) patients to that in biliary disease patients, to determine whether CP patients in early clinical stage have a…
- Trial name
- NCT02781987
- Testing
- chronic pancreatitis
- Volunteers
- 2,028 people
- Sponsor
- Changhai Hospital